219 related articles for article (PubMed ID: 29858025)
1. Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival.
Xie M; Wei S; Wu X; Li X; You Y; He C
Lung Cancer; 2018 Jul; 121():41-47. PubMed ID: 29858025
[TBL] [Abstract][Full Text] [Related]
2. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Significance of Notch1 and Fatty Acid Binding Protein 7 (FABP7) Expression in Resected Tracheobronchial Adenoid Cystic Carcinoma: A Multicenter Retrospective Study.
Xie M; Wu X; Zhang J; He C; Wei S; Huang J; Fu X; Gu Y
Cancer Res Treat; 2018 Oct; 50(4):1064-1073. PubMed ID: 29141398
[TBL] [Abstract][Full Text] [Related]
4. NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in Adenoid Cystic Carcinoma.
Panaccione A; Chang MT; Carbone BE; Guo Y; Moskaluk CA; Virk RK; Chiriboga L; Prasad ML; Judson B; Mehra S; Yarbrough WG; Ivanov SV
Clin Cancer Res; 2016 Apr; 22(8):2083-95. PubMed ID: 27084744
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of Notch1 receptor and clinicopathological High-Risk Predictors in lacrimal gland adenoid cystic carcinoma.
Anjum S; Sen S; Pushker N; Bajaj MS; Kashyap S; Bakhshi S; Chosdol K; Meel R; Sharma MC
Acta Ophthalmol; 2021 Dec; 99(8):e1467-e1473. PubMed ID: 33675181
[TBL] [Abstract][Full Text] [Related]
6. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.
Stoeck A; Lejnine S; Truong A; Pan L; Wang H; Zang C; Yuan J; Ware C; MacLean J; Garrett-Engele PW; Kluk M; Laskey J; Haines BB; Moskaluk C; Zawel L; Fawell S; Gilliland G; Zhang T; Kremer BE; Knoechel B; Bernstein BE; Pear WS; Liu XS; Aster JC; Sathyanarayanan S
Cancer Discov; 2014 Oct; 4(10):1154-67. PubMed ID: 25104330
[TBL] [Abstract][Full Text] [Related]
7. Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma.
Sajed DP; Faquin WC; Carey C; Severson EA; H Afrogheh A; A Johnson C; Blacklow SC; Chau NG; Lin DT; Krane JF; Jo VY; Garcia JJ; Sholl LM; Aster JC
Am J Surg Pathol; 2017 Nov; 41(11):1473-1482. PubMed ID: 28914715
[TBL] [Abstract][Full Text] [Related]
8. Whole Exome Sequencing of Lacrimal Gland Adenoid Cystic Carcinoma.
Sant DW; Tao W; Field MG; Pelaez D; Jin K; Capobianco A; Dubovy SR; Tse DT; Wang G
Invest Ophthalmol Vis Sci; 2017 May; 58(6):BIO240-BIO246. PubMed ID: 28820917
[TBL] [Abstract][Full Text] [Related]
9. The NOTCH1-HEY1 pathway regulates self-renewal and epithelial-mesenchymal transition of salivary adenoid cystic carcinoma cells.
Xie J; Lin LS; Huang XY; Gan RH; Ding LC; Su BH; Zhao Y; Lu YG; Zheng DL
Int J Biol Sci; 2020; 16(4):598-610. PubMed ID: 32025208
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
[TBL] [Abstract][Full Text] [Related]
11. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
Ferrarotto R; Eckhardt G; Patnaik A; LoRusso P; Faoro L; Heymach JV; Kapoun AM; Xu L; Munster P
Ann Oncol; 2018 Jul; 29(7):1561-1568. PubMed ID: 29726923
[TBL] [Abstract][Full Text] [Related]
12. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
Even C; Lassen U; Merchan J; Le Tourneau C; Soria JC; Ferte C; Ricci F; Diener JT; Yuen E; Smith C; Oakley GJ; Benhadji KA; Massard C
Invest New Drugs; 2020 Apr; 38(2):402-409. PubMed ID: 30953269
[TBL] [Abstract][Full Text] [Related]
13. The oncogenic effects of HES1 on salivary adenoid cystic carcinoma cell growth and metastasis.
Huang XY; Gan RH; Xie J; She L; Zhao Y; Ding LC; Su BH; Zheng DL; Lu YG
BMC Cancer; 2018 Apr; 18(1):436. PubMed ID: 29665790
[TBL] [Abstract][Full Text] [Related]
14. Notch activation promotes bone metastasis via SPARC inhibition in adenoid cystic carcinoma.
Zhang Y; Liu X; Zhu L; Zhou Z; Cui Y; Zhou CX; Li TJ
Oral Dis; 2024 Apr; 30(3):1220-1233. PubMed ID: 36951790
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival after resection of primary adenoid cystic and squamous cell carcinoma of the trachea and carina.
Gaissert HA; Grillo HC; Shadmehr MB; Wright CD; Gokhale M; Wain JC; Mathisen DJ
Ann Thorac Surg; 2004 Dec; 78(6):1889-96; discussion 1896-7. PubMed ID: 15560996
[TBL] [Abstract][Full Text] [Related]
16. Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma with and without NOTCH signaling pathway activation.
Feeney L; Hapuarachi B; Adderley H; Rack S; Morgan D; Walker R; Rauch R; Herz E; Kaye J; Harrington K; Metcalf R
Oral Oncol; 2022 Oct; 133():106028. PubMed ID: 35952580
[TBL] [Abstract][Full Text] [Related]
17. Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
Hanna GJ; Grover P; Elliott A; McGrath J; Xiu J; Sukari A; Johnson JM; Wise-Draper T
Clin Cancer Res; 2024 May; 30(10):2225-2232. PubMed ID: 38416410
[TBL] [Abstract][Full Text] [Related]
18. HEY1 is expressed independent of NOTCH1 and is associated with poor prognosis in head and neck squamous cell carcinoma.
Rettig EM; Bishop JA; Agrawal N; Chung CH; Sharma R; Zamuner F; Li RJ; Koch WM; Califano JA; Guo T; Gaykalova DA; Fakhry C
Oral Oncol; 2018 Jul; 82():168-175. PubMed ID: 29909892
[TBL] [Abstract][Full Text] [Related]
19. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
Wang K; Zhang Q; Li D; Ching K; Zhang C; Zheng X; Ozeck M; Shi S; Li X; Wang H; Rejto P; Christensen J; Olson P
Clin Cancer Res; 2015 Mar; 21(6):1487-96. PubMed ID: 25564152
[TBL] [Abstract][Full Text] [Related]
20. Anti-NOTCH1 therapy with OMP-52 M51 inhibits salivary adenoid cystic carcinoma by depressing epithelial-mesenchymal transition (EMT) process and inducing ferroptosis.
Li R; Hu Z; Qiao Q; Zhou D; Sun M
Toxicol Appl Pharmacol; 2024 Mar; 484():116825. PubMed ID: 38253083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
